Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(50.0%)

Phase 1

2(50.0%)

4Total

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT03749018Phase 2Active Not Recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Role: lead

NCT05821088Phase 2Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Role: lead

NCT03015896Phase 1Active Not Recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Role: lead

NCT03892044Phase 1Completed

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

Role: lead

All 4 trials loaded